CLINICAL OBSERVATION OF A PATIENT WITH CONTINUED GROWTH OF MALIGNANT GLIOMA: A CLINICAL CASE AND ANALYSIS OF CLINICAL AND THERAPEUTIC ASPECTS
Keywords:
glioblastoma, prognostic factors, neuro-oncologyAbstract
Continued growth of malignant gliomas, particularly glioblastoma, remains one of the most challenging problems in modern neuro-oncology due to the high biological aggressiveness of the tumor, its infiltrative growth pattern, and the limited effectiveness of currently available treatment approaches. Despite the use of multimodal therapy, including surgical intervention, radiotherapy, and pharmacological treatment, the majority of patients develop disease progression, which is associated with deterioration of neurological status and an unfavorable prognosis. The presented clinical case demonstrates the diagnostic features, repeated surgical treatment, and subsequent management of a patient with continued growth of glioblastoma.
References
Carlsson SK, Brothers SP, Wahlestedt C. Emerging treatment strategies for glioblastoma multiforme.EMBO Molecular Medicine. 2014;6(11):1359–1370.
Davis ME. Glioblastoma: overview of disease and treatment.Clinical Journal of Oncology Nursing. 2016;20(5 Suppl):S2–S8.
Ellingson BM, Wen PY, Cloughesy TF. Modified response assessment criteria for glioblastoma clinical trials.Neurotherapeutics. 2017;14:307–320.
Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.Journal of Clinical Oncology. 2009;27(28):4733–4740.
Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis.Biochemical and Biophysical Research Communications. 2017;482(2):253–259.
Lombardi G, De Salvo GL, Brandes AA, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised controlled phase 2 trial.The Lancet Oncology. 2019;20(1):110–119.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.Neuro-Oncology. 2021;23(8):1231–1251.
McKinnon C, Nandhabalan M, Murray SA, Plaha P. Glioblastoma: clinical presentation, multidisciplinary management and future directions.BMJ. 2021;374:n1560.
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review.JAMA. 2013;310(17):1842–1850.
Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018.Neuro-Oncology. 2021;23(Suppl 3):iii1–iii105.
Ostrom QT, Gittleman H, Stetson L, Virk SM, Barnholtz-Sloan JS. Epidemiology of gliomas.Cancer Treatment and Research. 2015;163:1–14.
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma.The Lancet Oncology. 2009;10(5):459–466.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.New England Journal of Medicine. 2005;352(10):987–996.
Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma.JAMA. 2017;318(23):2306–2316.
Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma.Cancer Epidemiology, Biomarkers & Prevention. 2014;23(10):1985–1996.
Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group.Journal of Clinical Oncology. 2010;28(11):1963–1972.
Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.Neuro-Oncology. 2020;22(8):1073–1113.
Weller M, Cloughesy T, Perry JR, Wick W. Molecular targeted therapy for glioblastoma: current status and future perspectives.Nature Reviews Clinical Oncology. 2013;10:695–706.
Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.NatureReviewsClinicalOncology. 2021;18:170–186.
Wick W, Gorlia T, Bady P, et al. Lomustine and bevacizumab in progressive glioblastoma.NewEnglandJournalofMedicine. 2017;377:1954–1963.
